# Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

> **NCT04849910** · PHASE1,PHASE2 · TERMINATED · sponsor: **Vor Biopharma** · enrollment: 67 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** VOR33
- **DRUG:** Mylotarg

## Key facts

- **NCT ID:** NCT04849910
- **Lead sponsor:** Vor Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-16
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-05-28
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Lack of Funding
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04849910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04849910, "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04849910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*